Value of adjuvant chemotherapy for patients with pT2N0M0 non-small cell lung cancer receiving radical resection.
Shiqi ChenSiqian YangYue ZhaoYang ZhangQingyuan HuangHaoxuan WuHong HuYihua SunYawei ZhangJiaqing XiangTing YeHaiquan ChenPublished in: Thoracic cancer (2023)
ACT was valuable for patients with pathological stage IIA (pT2bN0M0) and patients with radiological pure-solid LUAD of pathological stage IB. A combination of radiological features and pathological subtypes could be helpful when selecting patients with pT2N0M0 NSCLCs for ACT.
Keyphrases